<DOC>
	<DOCNO>NCT01611558</DOCNO>
	<brief_summary>To assess incidence drug-related adverse event Grade 3 high overall response associate ipilimumab treatment</brief_summary>
	<brief_title>Phase II Study Ipilimumab Monotherapy Recurrent Platinum-sensitive Ovarian Cancer</brief_title>
	<detailed_description>Condition : Ovarian Cancer , Second line , Third line , Fourth line</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Key Inclusion Criteria Ovarian cancer refractory resistant platinumbased therapy ( refactory=progression receive previous platinum regimen ; resistant=progression within 6 month previous platinum regimen ) Recipients platinum/taxanebased chemotherapy frontline regimen ovarian cancer An Eastern Cooperative Oncology Group performance status â‰¤1 Up 4 prior line therapy ovarian cancer Two group eligible : Group 1 . Women meet criterion progressive disease follow recent chemotherapeutic regimen require : Demonstrated partial response stable disease follow recent chemotherapy regimen Evaluable measurable disease , detect baseline compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan Received last dose recent chemotherapeutic regimen ovarian cancer within 4 12 week first administration ipilimumab Group 2 : Women disease progression receive follow last dose recent chemotherapeutic regimen require : Measurable disease CT MRI scan perform within 28 day first dose ipilimumab . Received last dose recent chemotherapeutic regimen ovarian cancer least 4 week prior first administration ipilimumab . Key Exclusion Criteria Histologic diagnosis borderline , low malignant potential epithelial carcinoma For Group 1 , woman complete response recent ovarian carcinomatherapy Presence know brain metastasis Second malignancy active within past 5 year , exception locally curable cancer need subsequent therapy Documented history severe autoimmune immunemediated symptomatic disease require prolonged systemic immunosuppressive treatment History motor neuropathy consider autoimmune origin grade 2 high peripheral neuropathy History toxic epidermal necrolysis Prior therapy immunosuppressive agent within last 2 year ( exclude lowdose corticosteroid ) prior therapy cytotoxic drug within 4 week Chronic use systemic immunosuppressive drug , ongoing use immunotherapy biologic therapy treatment cancer , prior use ipilimumab immunestimulating agent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>